Subcutaneous Semaglutide vs. Placebo as Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

JAMA

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, FEBRUARY 24, 2021

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2021.1831?guestAccessKey=5d38b335-f31a-4bd8-8fbf-167360ac109d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=022421

 

What The Study Did: This randomized clinical trial compares the effects of once-weekly subcutaneous semaglutide versussplacebo for weight management as an adjunct to intensive behavioral therapy with initial low-calorie diet in adults with overweight or obesity.

Authors: Thomas A. Wadden, Ph.D., of the University of Pennsylvania in Philadelphia, is the corresponding author.

 

(doi:10.1001/jama.2021.1831)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.